[ad_1]
Based as a spin-off from Sweden’s Chalmers College of Expertise, Fluicell made a giant entry into the 3D bioprinting market in 2019 with the launch of its Biopixlar platform. Right this moment, the corporate is getting ready to develop its system providing with the launch of a brand new machine, the Biopixlar AER. The bioprinter, which can change into obtainable on March 3, 2022, relies on the identical single-cell high-resolution bioprinting expertise as the unique Biopixlar however presents advances in automation and is extra compact.
The brand new Biopixlar AER is a transportable microfluidic bioprinting system, and Fluicell has particularly designed the compact system to suit inside customary cell tradition circulation hoods. This can allow researchers to extra simply use Fluicell’s single-cell bioprinting expertise together with different in vitro and 3D cell tradition applied sciences. Based on the Swedish bioprinting firm, its system is the primary of its variety to be designed in such a method.
Along with measurement, Fluicell has prioritized automation in creating its newest bioprinting system. The brand new machine introduces numerous course of automation options to streamline analysis workflows. The bioprinter additionally integrates distant management. The mixture of portability and enhanced automation make the Biopixlar AER appropriate for demanding functions in areas like medication, aerospace and deep-sea exploration.
“Biopixlar AER is actually a breakthrough technological achievement, representing a product providing completely in keeping with our general aspiration and ethos to hitch biology and expertise to be able to meet future healthcare wants,” says Fluicell CEO Victoire Viannay. “Biopixlar AER suits completely into Fluicell’s technique to make a distinction for researchers by rising the flexibleness, efficiency and adaptableness in bioprinting. Biopixlar AER can also be concentrating on new buyer segments that emphasize the power to parallelize and automate bioprinting and cell tradition processes.”
Gavin Jeffries, Fluicell CTO, provides: “The Biopixlar AER marks a milestone for Fluicell, delivering moveable fluidic bioprinting capabilities into typical researcher workflows. This new platform inside the Biopixlar household comes on account of specializing in person wants and anticipating future calls for inside the quickly accelerated bio-engineering sector. The AER showcases a variety of highly effective options tailor-made for at this time’s laboratory setting. A deep integration of fluidic, optical and movement management, mixed with a small footprint and course of automation, is designed to empowers researchers with bioprinting instruments in demanding environments. The rising data and desires inside the bioprinting discipline requires platforms to be tailor-made for each present and future analysis. This growth to the Biopixlar household, delivers on this chance.”
With its authentic bioprinter, the Biopixlar, Fluicell launched a brand new method to bioprinting. That’s, the system was the primary to make the most of single-cell bioprinting, which positions cells in three dimensions with out using a bioink. This expertise has the benefit of sustaining cells of their native setting and printing constructions with single-cell decision. The Biopixlar AER relies on this identical expertise.
[ad_2]
